Literature DB >> 11860083

Comparative in vitro activity of 16 antimicrobial agents against Actinobacillus pleuropneumoniae.

H Yoshimura1, M Takagi, M Ishimura, Y S Endoh.   

Abstract

Sixteen antimicrobial agents were tested for their activity against 68 isolates of Actinobacillus pleuropneumoniae by determining the minimum inhibitory concentrations (MICs). Ceftiofur and the fluoroquinolones danofloxacin and enrofloxacin were the most active compounds, with a MIC for 90% of the isolates (MIC90) of (0.05 microg/ml. The MIC90 values of benzylpenicillin, amoxicillin and aspoxicillin were 0.78 units/ml, 0.39 microg/ml and < or = 0.05 microg/ml, respectively. Three isolates (4.4%) were resistant to penicillins, but aspoxicillin was as active as ceftiofur against the susceptible isolates, with MICs of < or = 0.05 microg/ml for all isolates. Resistance to oxytetracycline, chloramphenicol and thiamphenicol occurred in 22 (32.4%), 14 (20.6%) and 15 (22.1%) of the isolates, respectively. Doxycycline was more active than oxytetracycline, with a MIC90 of 1.56 microg/ml as against 25 microg/ml. Florfenicol was not only as active as thiamphenicol, with a MIC for 50% of the isolates (MIC50) of 0.39 microg/ml, but also active against thiamphenicol-resistant isolates. All the isolates were susceptible to florfenicol. All the isolates were also susceptible to gentamicin, spectinomycin, tilmicosin, colistin and tiamulin. Of these, spectinomycin was the least active, with a MIC50 of 25 microg/ml, followed by tiamulin, with a MIC50 of 6.25 microg/ml. Of the 68 isolates tested, 49 (72.0%) were of serotype 2; 14 (20.5%) were of serotype 1; 2 each (3.0%) were of serotypes 5 and 6; and one was of serotype 7. Of the isolates, 23 (33.8%) were resistant to one or more of the major antibiotics. Antibiotic resistance was found only infrequently among serotype 2, with 5 (10.2%) of 49 isolates being resistant to chloramphenicol and/or oxytetracycline, while it occurred in 18 (94.7%) of the 19 isolates of other serotypes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11860083     DOI: 10.1023/a:1013397419995

Source DB:  PubMed          Journal:  Vet Res Commun        ISSN: 0165-7380            Impact factor:   2.459


  28 in total

1.  Antimicrobial susceptibility and serotypes of Actinobacillus (Haemophilus) pleuropneumoniae recovered from Missouri swine.

Authors:  W H Fales; L G Morehouse; K R Mittal; C Bean-Knudsen; S L Nelson; L D Kintner; J R Turk; M A Turk; T P Brown; D P Shaw
Journal:  J Vet Diagn Invest       Date:  1989-01       Impact factor: 1.279

2.  Serotyping of Actinobacillus (Haemophilus) pleuropneumoniae isolates from pigs in slaughterhouse.

Authors:  S Suzuki; T Takahashi; M Muramatsu; K Ohishi; M Nakajima; M Yamashita
Journal:  Nihon Juigaku Zasshi       Date:  1988-12

3.  In vitro activity of five tetracyclines and some other antimicrobial agents against four porcine respiratory tract pathogens.

Authors:  A Pijpers; B Van Klingeren; E J Schoevers; J H Verheijden; A S Van Miert
Journal:  J Vet Pharmacol Ther       Date:  1989-09       Impact factor: 1.786

4.  Antibiotic susceptibility of Haemophilus pleuropneumoniae and Pasteurella multocida isolates from swine.

Authors:  M Shimizu; K Kuninori; T Sakano; T Terashima
Journal:  Nihon Juigaku Zasshi       Date:  1982-04

5.  Isolation and antigenic characterization of Haemophilus parahaemolyticus from porcine pneumonia.

Authors:  C Chan; K Yamamoto; S Konishi; M Ogata
Journal:  Nihon Juigaku Zasshi       Date:  1978-02

6.  Experimental infections with Actinobacillus pleuropneumoniae in pigs--I. Comparison of five different parenteral antibiotic treatments.

Authors:  P Wallgren; T Segall; A Pedersen Mörner; A Gunnarsson
Journal:  Zentralbl Veterinarmed B       Date:  1999-05

7.  Serological characterisation and antimicrobial susceptibility of Actinobacillus pleuropneumoniae strains isolated from pigs in Spain.

Authors:  C B Gutiérrez; J I Rodríguez Barbosa; R I Tascón; L Costa; P Riera; E F Rodríguez Ferri
Journal:  Vet Rec       Date:  1995-07-15       Impact factor: 2.695

8.  Comparison of MICs of ceftiofur and other antimicrobial agents against bacterial pathogens of swine from the United States, Canada, and Denmark.

Authors:  S A Salmon; J L Watts; C A Case; L J Hoffman; H C Wegener; R J Yancey
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

9.  Efficacy of florfenicol on experimental Actinobacillus pleuropneumonia in pigs.

Authors:  Y Ueda; S Ohtsuki; N Narukawa
Journal:  J Vet Med Sci       Date:  1995-04       Impact factor: 1.267

10.  Drug-susceptibility and isolation of a plasmid in Haemophilus (Actinobacillus) pleuropneumoniae.

Authors:  H Ishii; Y Nakasone; S Shigehara; K Honma; Y Araki; S Iyobe; H Hashimoto
Journal:  Nihon Juigaku Zasshi       Date:  1990-02
View more
  5 in total

1.  Florfenicol pharmacokinetics in healthy adult alpacas after subcutaneous and intramuscular injection.

Authors:  K Holmes; D Bedenice; M G Papich
Journal:  J Vet Pharmacol Ther       Date:  2011-07-08       Impact factor: 1.786

2.  In vitro activities of florfenicol against bovine and porcine respiratory tract pathogens.

Authors:  Saskia Priebe; Stefan Schwarz
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

3.  Clinical Efficacy and Residue Depletion of 10% Enrofloxacin Enteric-Coated Granules in Pigs.

Authors:  Zhixin Lei; Qianying Liu; Bing Yang; Jincheng Xiong; Kun Li; Saeed Ahmed; Liping Hong; Pin Chen; Qigai He; Jiyue Cao
Journal:  Front Pharmacol       Date:  2017-05-23       Impact factor: 5.810

4.  In vitro and in vivo Synergistic Effects of Florfenicol and Thiamphenicol in Combination Against Swine Actinobacillus pleuropneumoniae and Pasteurella multocida.

Authors:  Porjai Rattanapanadda; Hung-Chih Kuo; Thomas W Vickroy; Chi-Hsuan Sung; Tirawat Rairat; Tsai-Lu Lin; Sze-Yu Yeh; Chi-Chung Chou
Journal:  Front Microbiol       Date:  2019-10-30       Impact factor: 5.640

5.  Isolation of atypical genotype Actinobacillus pleuropneumoniae serotype 6 in Japan.

Authors:  Hiroya Ito; Kiyohito Katsuragi; Shunsuke Akama; Hirofumi Yuzawa
Journal:  J Vet Med Sci       Date:  2013-12-25       Impact factor: 1.267

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.